0370 270 6000

already registered?

Please sign in with your existing account details.

need to register?

Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.

Privacy statement - Terms and conditions

a prescription for infringement? Actavis and Warner-Lambert - intention, or foreseeability?

26 October 2016

The Court of Appeal has handed down its judgment on the long-running Pregabalin saga. The patent was found invalid, so the reasoning below is non-binding, but adds clarity to when a claim in a patent for an alternative use of a medicine (a.k.a. 'Swiss-Form Claims') is infringed by a product which is labelled for use for a different purpose to that in the patent.

Previously, to infringe, the company selling the non-patented product had to “foresee that the product would be intentionally administered [by a doctor or pharmacist] for the use which was patented”. Floyd LJ has now clarified that the test is whether the manufacturer can “foresee that there will be intentional use” which matches the patented use.

Manufacturers selling an 'alternative use' product will not be able to avoid liability by simply having the proposed use on the label (and not the patented use). To negate the 'foreseeability' of intentional use for the patented purpose, additional steps such as notifying those prescribing the product that it must not be prescribed for the patented purpose, or applying warnings to this effect should be considered.

related opinions

IR35 changes - six months and counting...

In his 2018 Autumn Budget, the then Chancellor, Phillip Hammond, announced a significant change to the way liability for IR35 breaches will be dealt with for private sector companies from April 2020.

View blog

Marriott International: a look behind the ICO’s £99m fine and what this means for corporate acquisitions

Last month, the Information Commissioner’s Office (ICO) announced notice of its intention to fine (NOI) Marriott International, Inc. £99m for infringements of the GDPR.

View blog

SFO fail to secure individual criminal convictions following Deferred Prosecution Agreement

On 16 July 2019 the Serious Fraud Office released details of the Deferred Prosecution Agreement reached with Sarclad Ltd in July 2016.

View blog

Supreme Court backs employers seeking to enforce restrictive covenants: Tillman v Egon Zehnder Ltd

The Supreme Court in Tillman v Egon Zehnder Ltd has determined that where post-termination restrictive covenants (i.e. “non-compete” clauses) in employment contracts go further than reasonably necessary to protect an employer’s business interests, it can apply the ‘blue pencil test,’ severing the offending words and leaving the remaining enforceable clause in place.

View blog

mailing list sign up

Select which mailings you would like to receive from us.

Sign up